Is Murepavadin safe?
Kidney injury in over half in phase 3
Acute kidney injury is the established problem. More than half of treated patients in PRISM-MDR developed it. That rate was well above the control arm. It was also above what the disease alone produces. The kidneys clear the drug. No one has explained the cause of the toxicity. It may be shared with colistin and other cationic peptides. Phase 1 data showed no other major signal. But exposure was short and in healthy people. It is not known whether the inhaled form avoids the kidney problem, and that program is now discontinued. 2345
Read the full Murepavadin page
More on Murepavadin
Citations
- Martin-Loeches 2018, Expert Rev Anti Infect Ther: Murepavadin, a new antibiotic class in the pipeline doi.org
- Wach 2018, Antimicrob Agents Chemother: pharmacokinetics and safety of intravenous murepavadin in healthy adults, single and multiple ascending doses doi.org
- Polyphor press release, May 2019: enrollment halted in the phase 3 PRISM trials of murepavadin biospace.com
- Polyphor press release, July 2019: phase 3 PRISM studies of intravenous murepavadin closed biospace.com
- Cystic Fibrosis Foundation: inhaled murepavadin pipeline entry (discontinued) apps.cff.org
Reference information only, not medical advice. Drawn from the Murepavadin article, fact-checked against the cited sources. No dosing anywhere on this site.